IE
NGNE icon

Israel Englander’s Neurogene NGNE Stock Holding History

Israel Englander’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,720
Closed -$359K – 7288
2021
Q4 		$359K Buy
+3,720
New +$453K ﹤0.01% 5351

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Israel Englander's NGNE Position: Q2 2026 in Review

Israel Englander reduced its Neurogene (NGNE) stake by 79% in Q2 2026, selling an estimated $4.46M and leaving 42,734 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #4126.

Israel Englander first reported a position in NGNE in Q3 2015 and has held it in 37 quarters since. The position peaked at $8.57M in Q1 2020. 111 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Israel Englander held 42,734 shares of Neurogene worth $1.34M as of Q2 2026.
  • Israel Englander sold 162,075 Neurogene shares in Q2 2026, an estimated $4.46M.
  • Neurogene made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4126 holding.
  • Israel Englander first reported a position in Neurogene in Q3 2015 and has held it in 37 quarters since.
  • Israel Englander's Neurogene position peaked at $8.57M in Q1 2020.
  • 111 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.